Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of weekly somatrogon versus daily Genotropin in prepubertal children with growth hormone deficiency
MOH_2017-12-09_000690Phase 3Completed
- Sponsor
- OPKO Biologics
- Start
- Jul 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by OPKO Biologics. Primary endpoints: Non-inferior efficacy of weekly somatrogon versus daily Genotropin and Safety and tolerability. Started Jul 2017; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on MOH_2017-12-09_000690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-09_000690.